OL-FS13 Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting miR-21-3p Expression

Curr Neuropharmacol. 2023;21(12):2550-2562. doi: 10.2174/1570159X21666230502111013.

Abstract

Background: OL-FS13, a neuroprotective peptide derived from Odorrana livida, can alleviate cerebral ischemia-reperfusion (CI/R) injury, although the specific underlying mechanism remains to be further explored.

Objective: The effect of miR-21-3p on the neural-protective effects of OL-FS13 was examined.

Methods: In this study, the multiple genome sequencing analysis, double luciferase experiment, RT-qPCR, and Western blotting were used to explore the mechanism of OL-FS13.

Results: Showed that over-expression of miR-21-3p against the protective effects of OL-FS13 on oxygen- glucose deprivation/re-oxygenation (OGD/R)-damaged pheochromocytoma (PC12) cells and in CI/R-injured rats. miR-21-3p was then found to target calcium/calmodulin-dependent protein kinase 2 (CAMKK2), and its overexpression inhibited the expression of CAMKK2 and phosphorylation of its downstream adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK), thereby inhibiting the therapeutic effects of OL-FS13 on OGD/R and CI/R. Inhibition of CAMKK2 also antagonized up-regulated of nuclear factor erythroid 2-related factor 2 (Nrf-2) by OL-FS13, thereby abolishing the antioxidant activity of the peptide.

Conclusion: Our results showed that OL-FS13 alleviated OGD/R and CI/R by inhibiting miR-21-3p to activate the CAMKK2/AMPK/Nrf-2 axis.

Keywords: CAMKK2/AMPK pathway; Cerebral ischemia-reperfusion; microRNA; neuroprotective; oxidative stress; peptide.

MeSH terms

  • AMP-Activated Protein Kinases / pharmacology
  • AMP-Activated Protein Kinases / therapeutic use
  • Animals
  • Apoptosis
  • Brain Ischemia* / metabolism
  • MicroRNAs* / metabolism
  • Neuroprotection
  • Oxygen / metabolism
  • Rats
  • Reperfusion Injury*

Substances

  • MicroRNAs
  • AMP-Activated Protein Kinases
  • Oxygen
  • mirn21 microRNA, rat